Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, comments on the use of tafasitamab, a CD19-targeted monoclonal antibody, and immune checkpoint inhibitors for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Tafasitamab for R/R DLBCL
Теги
Speaker: Ulrich JägerInstitution: Medical University of ViennaFormat: InterviewEvent: EHA 2021Subject: Diffuse Large B-Cell LymphomaSubject: LymphomaSubject: Non-Hodgkin LymphomaSubject: B-Cell LymphomaMedicines: TafasitamabMedicines: AntibodiesMedicines: LenalidomideField: TreatmentField: Immuno-OncologyField: Perspectivesimmune checkpoint inhibitors
